Fulcrum Therapeutics (FULC) Competitors $6.58 +0.07 (+1.01%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. CALT, ETNB, OCUL, AMPH, BGM, AUPH, WVE, GYRE, PAHC, and MLYSShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Ocular Therapeutix (OCUL), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Calliditas Therapeutics AB (publ) 89bio Ocular Therapeutix Amphastar Pharmaceuticals Qilian International Holding Group Aurinia Pharmaceuticals Wave Life Sciences Gyre Therapeutics Phibro Animal Health Mineralys Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking. Do analysts rate FULC or CALT? Fulcrum Therapeutics currently has a consensus price target of $4.50, indicating a potential downside of 31.57%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, FULC or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M4.44-$97.33M-$0.07-93.94Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media prefer FULC or CALT? In the previous week, Fulcrum Therapeutics had 12 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 12 mentions for Fulcrum Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Fulcrum Therapeutics' average media sentiment score of 1.02 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fulcrum Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral Does the MarketBeat Community believe in FULC or CALT? Fulcrum Therapeutics received 72 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 61.11% of users gave Fulcrum Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9961.11% Underperform Votes6338.89% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Do institutionals and insiders believe in FULC or CALT? 89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, FULC or CALT? Fulcrum Therapeutics has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Is FULC or CALT more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Fulcrum Therapeutics' return on equity of -7.31% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% SummaryFulcrum Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 17 factors compared between the two stocks. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$360.58M$6.58B$5.41B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-21.559.2126.7719.96Price / Sales4.44257.57395.44121.37Price / CashN/A65.8538.2534.62Price / Book1.736.576.874.60Net Income-$97.33M$144.25M$3.23B$248.27M7 Day Performance16.80%5.13%5.32%2.28%1 Month Performance90.06%9.67%13.56%16.43%1 Year Performance-13.93%-0.88%17.86%8.15% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics0.7716 of 5 stars$6.58+1.0%$4.50-31.6%-15.5%$360.58M$80M-21.55100Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ETNB89bio2.8861 of 5 stars$8.11+5.3%$27.25+236.0%+1.0%$1.18BN/A-2.7940Positive NewsOCULOcular Therapeutix4.2938 of 5 stars$7.39+4.7%$16.25+119.9%+20.8%$1.18B$59.65M-5.60230Positive NewsAMPHAmphastar Pharmaceuticals4.2878 of 5 stars$24.34+1.0%$32.33+32.8%-41.8%$1.16B$731.97M8.111,620BGMQilian International Holding GroupN/A$11.42+3.5%N/AN/A$1.11B$25.10M0.00298Gap DownAUPHAurinia Pharmaceuticals2.4527 of 5 stars$8.12+1.5%$11.50+41.6%+43.6%$1.11B$235.13M-54.13300WVEWave Life Sciences4.4236 of 5 stars$6.60+0.2%$21.17+220.7%+2.5%$1.02B$108.30M-5.95240Positive NewsGap DownGYREGyre Therapeutics0.2805 of 5 stars$10.83+13.6%N/A-21.0%$1.02B$105.76M541.5040PAHCPhibro Animal Health3.5513 of 5 stars$24.50+9.0%$20.00-18.4%+32.1%$992.32M$1.11B51.041,860Positive NewsMLYSMineralys Therapeutics2.7745 of 5 stars$15.01+2.5%$33.00+119.9%+25.7%$973.79MN/A-4.1228 Related Companies and Tools Related Companies CALT Competitors ETNB Competitors OCUL Competitors AMPH Competitors BGM Competitors AUPH Competitors WVE Competitors GYRE Competitors PAHC Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
